Hepatitis E: a concise review of virology, epidemiology, clinical presentation and therapy

M.C. Donnelly, L. Scobie, C.L. Crossan, H. Dalton, P.C. Hayes, K. J. Simpson

Research output: Contribution to journalArticle

23 Downloads (Pure)

Abstract

Background
Hepatitis E virus (HEV) is a leading cause of acute icteric hepatitis and acute liver failure in the developing world. During the last decade, there has been increasing recognition of autochthonous (locally acquired) HEV infection in developed countries. Chronic HEV infection is now recognised, and in transplant recipients this may lead to cirrhosis and organ failure.

Aim
To detail current understanding of the molecular biology of HEV, diagnostic and therapeutic strategies and propose future directions for basic science and clinical research.

Methods
PubMed was searched for English language articles using the key words “hepatitis E”, “viral hepatitis”, “autochthonous infection”, “antiviral therapy”, “liver transplantation”, “acute”, “chronic”, “HEV”, “genotype”, “transmission” “food-borne”, “transfusion”. Additional relevant publications were identified from article reference lists.

Results
There has been increasing recognition of autochthonous HEV infection in Western countries, mainly associated with genotype 3. Chronic HEV infection has been recognised since 2008, and in transplant recipients this may lead to cirrhosis and organ failure. Modes of transmission include food-borne transmission, transfusion of blood products and solid organ transplantation. Ribavirin therapy is used to treat patients with chronic HEV infection, but new therapies are required as there have been reports of treatment failure with ribavirin.

Conclusions
Autochthonous HEV infection is a clinical issue with increasing burden. Future work should focus on increasing awareness of HEV infection in the developed world, emphasising the need for clinicians to have a low threshold for HEV testing, particularly in immunosuppressed patients. Patients at potential risk of chronic HEV infection must also be educated and given advice regarding prevention of infection.
Original languageEnglish
Pages (from-to)126-141
Number of pages16
JournalAlimentary Pharmacology and Therapeutics
Volume46
Issue number2
Early online date27 Apr 2017
DOIs
Publication statusPublished - Jul 2017

Fingerprint

Hepatitis E
Virology
Epidemiology
Infection
Therapeutics
Ribavirin
Hepatitis
Fibrosis
Genotype
Food
Acute Liver Failure
Organ Transplantation
Treatment Failure
Developed Countries
Blood Transfusion
Liver Transplantation
Antiviral Agents
Publications
Molecular Biology
Language

Keywords

  • hepatitis E virus
  • epidemiology
  • review article
  • virology

Cite this

Donnelly, M.C. ; Scobie, L. ; Crossan, C.L. ; Dalton, H. ; Hayes, P.C. ; Simpson, K. J. . / Hepatitis E: a concise review of virology, epidemiology, clinical presentation and therapy. In: Alimentary Pharmacology and Therapeutics. 2017 ; Vol. 46, No. 2. pp. 126-141.
@article{860eecc36859467daaaa02cbf4cbf25c,
title = "Hepatitis E: a concise review of virology, epidemiology, clinical presentation and therapy",
abstract = "BackgroundHepatitis E virus (HEV) is a leading cause of acute icteric hepatitis and acute liver failure in the developing world. During the last decade, there has been increasing recognition of autochthonous (locally acquired) HEV infection in developed countries. Chronic HEV infection is now recognised, and in transplant recipients this may lead to cirrhosis and organ failure.AimTo detail current understanding of the molecular biology of HEV, diagnostic and therapeutic strategies and propose future directions for basic science and clinical research.MethodsPubMed was searched for English language articles using the key words “hepatitis E”, “viral hepatitis”, “autochthonous infection”, “antiviral therapy”, “liver transplantation”, “acute”, “chronic”, “HEV”, “genotype”, “transmission” “food-borne”, “transfusion”. Additional relevant publications were identified from article reference lists.ResultsThere has been increasing recognition of autochthonous HEV infection in Western countries, mainly associated with genotype 3. Chronic HEV infection has been recognised since 2008, and in transplant recipients this may lead to cirrhosis and organ failure. Modes of transmission include food-borne transmission, transfusion of blood products and solid organ transplantation. Ribavirin therapy is used to treat patients with chronic HEV infection, but new therapies are required as there have been reports of treatment failure with ribavirin.ConclusionsAutochthonous HEV infection is a clinical issue with increasing burden. Future work should focus on increasing awareness of HEV infection in the developed world, emphasising the need for clinicians to have a low threshold for HEV testing, particularly in immunosuppressed patients. Patients at potential risk of chronic HEV infection must also be educated and given advice regarding prevention of infection.",
keywords = "hepatitis E virus, epidemiology, review article, virology",
author = "M.C. Donnelly and L. Scobie and C.L. Crossan and H. Dalton and P.C. Hayes and Simpson, {K. J.}",
note = "Acceptance email in SAN AAM: 12m embargo Funding note: Financial support: none.",
year = "2017",
month = "7",
doi = "10.1111/apt.14109",
language = "English",
volume = "46",
pages = "126--141",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "John Wiley & Sons",
number = "2",

}

Hepatitis E: a concise review of virology, epidemiology, clinical presentation and therapy. / Donnelly, M.C. ; Scobie, L.; Crossan, C.L.; Dalton, H.; Hayes, P.C.; Simpson, K. J. .

In: Alimentary Pharmacology and Therapeutics, Vol. 46, No. 2, 07.2017, p. 126-141.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hepatitis E: a concise review of virology, epidemiology, clinical presentation and therapy

AU - Donnelly, M.C.

AU - Scobie, L.

AU - Crossan, C.L.

AU - Dalton, H.

AU - Hayes, P.C.

AU - Simpson, K. J.

N1 - Acceptance email in SAN AAM: 12m embargo Funding note: Financial support: none.

PY - 2017/7

Y1 - 2017/7

N2 - BackgroundHepatitis E virus (HEV) is a leading cause of acute icteric hepatitis and acute liver failure in the developing world. During the last decade, there has been increasing recognition of autochthonous (locally acquired) HEV infection in developed countries. Chronic HEV infection is now recognised, and in transplant recipients this may lead to cirrhosis and organ failure.AimTo detail current understanding of the molecular biology of HEV, diagnostic and therapeutic strategies and propose future directions for basic science and clinical research.MethodsPubMed was searched for English language articles using the key words “hepatitis E”, “viral hepatitis”, “autochthonous infection”, “antiviral therapy”, “liver transplantation”, “acute”, “chronic”, “HEV”, “genotype”, “transmission” “food-borne”, “transfusion”. Additional relevant publications were identified from article reference lists.ResultsThere has been increasing recognition of autochthonous HEV infection in Western countries, mainly associated with genotype 3. Chronic HEV infection has been recognised since 2008, and in transplant recipients this may lead to cirrhosis and organ failure. Modes of transmission include food-borne transmission, transfusion of blood products and solid organ transplantation. Ribavirin therapy is used to treat patients with chronic HEV infection, but new therapies are required as there have been reports of treatment failure with ribavirin.ConclusionsAutochthonous HEV infection is a clinical issue with increasing burden. Future work should focus on increasing awareness of HEV infection in the developed world, emphasising the need for clinicians to have a low threshold for HEV testing, particularly in immunosuppressed patients. Patients at potential risk of chronic HEV infection must also be educated and given advice regarding prevention of infection.

AB - BackgroundHepatitis E virus (HEV) is a leading cause of acute icteric hepatitis and acute liver failure in the developing world. During the last decade, there has been increasing recognition of autochthonous (locally acquired) HEV infection in developed countries. Chronic HEV infection is now recognised, and in transplant recipients this may lead to cirrhosis and organ failure.AimTo detail current understanding of the molecular biology of HEV, diagnostic and therapeutic strategies and propose future directions for basic science and clinical research.MethodsPubMed was searched for English language articles using the key words “hepatitis E”, “viral hepatitis”, “autochthonous infection”, “antiviral therapy”, “liver transplantation”, “acute”, “chronic”, “HEV”, “genotype”, “transmission” “food-borne”, “transfusion”. Additional relevant publications were identified from article reference lists.ResultsThere has been increasing recognition of autochthonous HEV infection in Western countries, mainly associated with genotype 3. Chronic HEV infection has been recognised since 2008, and in transplant recipients this may lead to cirrhosis and organ failure. Modes of transmission include food-borne transmission, transfusion of blood products and solid organ transplantation. Ribavirin therapy is used to treat patients with chronic HEV infection, but new therapies are required as there have been reports of treatment failure with ribavirin.ConclusionsAutochthonous HEV infection is a clinical issue with increasing burden. Future work should focus on increasing awareness of HEV infection in the developed world, emphasising the need for clinicians to have a low threshold for HEV testing, particularly in immunosuppressed patients. Patients at potential risk of chronic HEV infection must also be educated and given advice regarding prevention of infection.

KW - hepatitis E virus

KW - epidemiology

KW - review article

KW - virology

U2 - 10.1111/apt.14109

DO - 10.1111/apt.14109

M3 - Article

VL - 46

SP - 126

EP - 141

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 2

ER -